Serum placental growth factor in late first trimester of pregnancy for prediction of preeclampsia in primigravida - a case control study
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20164641Keywords:
Gestational hypertension, PGLF, PreeclampsiaAbstract
Background: We studied the correlation of serum PLGF levels at 11-14 weeks in primigravida for prediction of future preeclampsia in a prospective nested case control study and estimated the critical levels of PLGF for possible use as screening test.
Methods: Subjects with preeclampsia/gestational hypertension were taken as cases with an equal number of controls.
Results: Out of 300 participants, final analysis was possible in 291 subjects. Thirty five were cases; two had early PE, 15 late PE and 18 had GH. PLGF level was lower in cases (20 pg/ml) compared to controls (79 pg/ml). PLGF was significantly lower in PE cases (15 pg/ml) compared to GH cases (34 pg/ml). PLGF had maximum area under the ROC curve (AUC) for PE with value of 0.867. Further, late PE had more AUC (0.853) as compared to GH (0.759). The cut off value for prediction of PE was found to be <30 pg/ml with 88.2% sensitivity and 71.4% specificity.
Conclusions: PLGF levels were significantly lower in first trimester serum samples of subjects who later developed either preeclampsia or gestational hypertension. PLGF had better detection rate for PE and late PE as compared to GH.
Metrics
References
American College of Obstetricians and Gynecologists. Hypertension in Pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122-31.
Lai J, Pinas A, Poon LC, Agathokleous M, Nicolaides KH. Maternal serum placental growth factor, pregnancy-associated plasma protein-a and free β-human chorionic gonadotrophin at 30-33 weeks in the prediction of preeclampsia. Fetal Diagn Ther. 2013;33:164-72.
Myatt L, Clifton RG, Roberts JM, Spong CY, Hauth JC, Varner MW, et al. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol. 2012; 119:1234-42.
Myers JE, Kenny LC, McCowan LM, Chan EH, Dekker GA, Poston L, et al: Angiogenic factors combined with clinical risk factors to predict preterm preeclampsia in nulliparous women: a predictive test accuracy study. Br J Obstet Gynaecol. 2013;120:1215-3.
Parra-Cordero M, Rodrigo R, Barja P, Bosco C, Rencoret G, Sepúlveda-Martinez A, et al. Prediction of early and late preeclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. Ultrasound Obstet Gynecol. 2013;41:538-44.
Schneuer FJ, Nassar N, Guilbert C, Tasevski V, Ashton AW, Morris JM, et al. First trimester screening of serum soluble fms-like tyrosine kinase-1 and placental growth factor predicting hypertensive disorders of pregnancy. Pregnancy Hypertens. 2013;3:215-21.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late preeclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn. 2011;31:66-74.
Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009;53:812-8.
Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation. 2010;122:478-87.
Youssef A, Righetti F, Morano D, Rizzo N, Farina A. Uterine artery Doppler and biochemical markers (PAPP-A, PIGF, sFlt-1, P-selectin, NGAL) at 11 + 0 to 13 + 6 weeks in the prediction of late (> 34 weeks) preeclampsia. Prenat Diagn. 2011;31:1141-6.
Ghosh SK, Raheja S, Tuli A, Raghunandan C, Agarwal S. Serum placental growth factor as a predictor of early onset preeclampsia in overweight/obese pregnant women. J Am Soc Hypertens. 2013;7:137-48.